Melissa Carter
Medical · Goodlettsville, TNNPI 1881634442
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,933 of the $8,943 with a category attached, or 88.7%. It is spread thinly across 35 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,361 and has fallen 58.6% since, to $978 in 2025. Among medical clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Intuitive Surgical$1K
- AbbVie$931
- Mannkind Corporation$872
- Lilly USA, LLC$690
- Pfizer$502
- plus $3K from 29 others
What the payments were for
- Travel & lodging$1,01011%
- Food & beverage$7,93389%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 107 | $2,051 |
| Intuitive Surgical | 5 | $1,010 |
| AbbVie | 70 | $931 |
| Mannkind Corporation | 59 | $872 |
| Lilly USA, LLC | 48 | $690 |
| Pfizer | 26 | $502 |
| Xeris Pharmaceuticals, Inc. | 19 | $421 |
| Sanofi-aventis U.S. LLC | 19 | $322 |
| Amgen | 15 | $311 |
| AstraZeneca(2 entities) | 16 | $261 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $162 |
| Biohaven Pharmaceuticals, Inc. | 7 | $151 |
| Shield Therapeutics Inc | 7 | $141 |
| Exact Sciences | 7 | $115 |
| Merck | 6 | $102 |
| Esperion Therapeutics, Inc. | 5 | $100 |
| Astellas Pharma US Inc | 4 | $98 |
| Insulet Corporation | 4 | $82 |
| Boehringer Ingelheim | 4 | $80 |
| Zealand Pharma US, Inc. | 3 | $74 |
| Stryker | 1 | $68 |
| Novartis | 3 | $60 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| RGH Enterprises LLC | 1 | $42 |
| Hologic Sales And Service, LLC | 1 | $37 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| BETA Bionics, Inc. | 1 | $29 |
| Bausch Health US, LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
| Endogastric Solutions, Inc | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$985
- RYBELSUS$122
How this compares
$8,943 in reported general payments places this provider in the 95th percentile of 480 medical providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 130 | $151,379 |
| JardianceEmpagliflozin | 93 | $87,355 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 45 | $49,736 |
| MounjaroTirzepatide | 35 | $46,896 |
| FarxigaDapagliflozin Propanediol | 52 | $37,956 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 16 | $26,737 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $26,325 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $21,274 |
| Novolog FlexpenInsulin Aspart | 39 | $15,730 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $15,500 |
| Bydureon BciseExenatide Microspheres | 12 | $14,297 |
| EliquisApixaban | 21 | $14,260 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 46 | $5,053 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 26 | $2,270 |
| Metformin Hcl ErMetformin Hcl | 162 | $1,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $2,051 | $178,116146 claims |
| Boehringer IngelheimJardiance | $80 | $87,35593 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $322 | $49,73645 claims |
| Lilly USA, LLCMounjaro | $690 | $46,89635 claims |
| AstraZenecaFarxiga | $261 | $37,95652 claims |
| PfizerEliquis | $502 | $14,26021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 480 medical providers in Tennessee.
Other medical in Goodlettsville
- Jeannie SwaffordGoodlettsville$7K
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
- Evan HatfillNashville$18K
- Meredith McDanielChattanooga$17K
- Janet BreedingKnoxville$15K
- Paul MabenKnoxville$13K
- Hannah KirkGreeneville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.